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doi:10.1016/j.numecd.2011.04.007Abstract Background and aims: We compared direct costs of diabetic and non diabetic
people covered by the Italian National Health System, focusing on the influence of age, sex,
type of diabetes and treatment.
Methods and results: Diabetic people living in Turin were identified through the Regional Dia-
betes Registry and the files of hospital discharges and prescriptions. Data sources were linked
to the administrative databases to assess health care services used by diabetic (n Z 33,792)
and non diabetic people(n Z 863,123). Data were analyzed with the two-part model; the esti-
mated direct costs per person/year were V3660.8 in diabetic people and V895.6 in non dia-
betic people, giving a cost ratio of 4.1. Diabetes accounted for 11.4% of total health care
expenditure. The costs were attributed to hospitalizations (57.2%), drugs (25.6%), to outpa-
tient care (11.9%), consumable goods (4.4%) and emergency care (0.9%). Estimated costs
increased from V 2670.8 in diabetic people aged <45 years to V 3724.1 in those aged >74
years, the latter representing two third of the diabetic cohort; corresponding figures in non
diabetic people were V 371.6 and V 2155.9. In all expenditure categories cost ratios of dia-
betic vs non diabetic people were higher in people aged <45 years, in type 1 diabetes and
in insulin-treated type 2 diabetes.
Conclusion: Direct costs are 4-fold higher in diabetic than in non diabetic people, mainly due
to care of the elderly and inpatient care. In developed countries, demographic changes will
have a profound impact on costs for diabetes in next years.
ª 2011 Elsevier B.V. All rights reserved.633 6709; fax: þ39 11 670 8477.
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+ MODELPrevalence of diabetes is increasing worldwide [1]. In
developed countries, the disease is more frequent in the
frailer subgroups of the population, ethnic minorities,
women, people with low socioeconomic level and the
elderly [2,3]. Public health interventions are needed at
individual and population levels to improve lifestyle habits
and to identify asymptomatic people. From a public health
perspective, however, there is also the need to recognize
that increasing ageing of the general population and
improved survival of diabetic people will necessarily cause
an increasing trend in the prevalence of the disease and,
finally, a profound impact on overall health care costs [4].
Focusing on national strategies of diabetes prevention is
necessary, but a parallel realistic planning of health care
costs due to burden of the disease is needed [5,6].
To perform optimization of resources allocation, policy
makers need updated epidemiological data on the impact of
the disease. Comparing diabetic and non diabetic
population-based cohorts living in the same area allows to
estimate the excess of costs attributable to the disease,
taking into account the effect of confounding factors, such
as age and sex. This approach allows a more accurate
extrapolation of the amount of expenditure due to the
disease at a country level. Few studies, however, have
provided detailed figures of direct costs of diabetic people
[7e15]. They mainly examined clinic-based cohorts or
national representative samples of diabetic people and then
extrapolated the total costs of the disease through the
bottom-up approach, rather than identifying a large
population-based cohort of diabetic and non diabetic people
and then measuring the incremental cost of the disease.
In previous reports of the Turin Study, a large population-
based cohort of Italian people with diabetes, we have
assessed prevalence of the disease [3], its impact on
prescription costs [16] and quality of health care provided as
part of the National Health System [17]. In this report, we
have expanded our database to estimate the overall impact
of diabetes on direct costs and to assess heterogeneity in
costs by sex, age groups, type of diabetes and hypoglycemic
treatment.Methods
The study base includes all residents in the city of Turin
(896,915 inhabitants) with a diagnosis of diabetes on 31 July
2003. As described in detail elsewhere [3,16], three data
sources were employed to identify diabetic people: the file
of subjects registered in the Regional Diabetes Registry (an
administrative database including all people who obtained
exemption from payment of drugs, syringes, and glucose
monitoring strips due to a diagnosis of diabetes mellitus),
the file of prescriptions of hypoglycemic drugs, and the file
of persons discharged from regional and national hospitals
with a primary or secondary diagnosis of diabetes. All data
sources were matched by a deterministic linkage procedure
using the fiscal code as unique identifier, and were linked
to the Turin Population Register to include only people
alive on July 31, 2003 and to determine each individual’s
educational level [3]. Type of diabetes was classified
according to information provided by the Regional Diabetes
Registry and the Registry of type 1 diabetes of the ProvincePlease cite this article in press as: Bruno G, et al., Direct costs in dia
Italy, Nutrition, Metabolism & Cardiovascular Diseases (2011), doi:10.of Turin [18]. People with unclassified diabetes were
considered as type 1 diabetes if they were <30 years, type
2 diabetes elsewhere (n Z 5766). Treatment was classified
into three groups: diet only, oral hypoglycemic drugs and
insulin. Information about therapy was retrieved from the
Regional Diabetes Registry and, for patients not registered
in this data source, from the files of prescriptions of
hypoglycemic drugs. Subjects who were prescribed both
insulin and oral hypoglycemic drugs were assigned to the
insulin treatment category; all diabetic individuals not
registered in the Regional Diabetes Registry and in the file
of hypoglycemic drug prescriptions were identified through
the third data source (hospital discharges) and were
considered within the diet treatment category (1986
individuals).
All Italian citizens, irrespective of social class or
income, are cared for by a general practitioner and obtain
all health care services as part of the National Health
System, which are recorded in a regional database. All drug
prescriptions, laboratory tests, specialist medical exami-
nations, prescriptions related to diabetes care (test strips,
syringes, glucometers), hospital discharges and emergency
room admission from August 1, 2003 to July 31, 2004 were
linked to the overall Turin population. Health care services
used by diabetic and non-diabetic people and their costs,
as defined by regional and governmental contracts, were
then analyzed. Private health care services were not
considered, as data were not available; their impact on
overall health care costs, however, is generally quite low.
The cumulative cost for a drug was calculated by multi-
plying the units prescribed by the cost for each fill. The
cumulative cost for hospitalizations was calculated by
multiplying each episode of hospitalization by the unit cost
for each Diagnosis Related Group (DRG). The cumulative
costs for specialist visits, laboratory tests and other
consumable goods were calculated by multiplying each of
them by their unit cost. The proportion of individuals with
specific outpatient visits or tests and their mean costs per
cared patient were calculated using the main specialist
branch involved in each episode of care. The cost for
emergency care was based on laboratory tests and
specialist consultations performed.
The statistical distribution of costs was strongly asym-
metric due to the high number of subjects not using health
services, particularly among non-diabetic people. Esti-
mated costs per person/year for people with and without
diabetes were then calculated by means of the two-part





ZPððY > 0=XÞ E ðY=X; Y > 0ÞÞ
where Y represents the cost and X represents the vector of
covariates [18].
The first part was fitted by logistic models; odds ratios for
probabilities of using health services were then estimated.
The second part was estimated by using a generalized linear
model assuming a gamma distribution of costs and a loga-
rithmic link function; cost ratios of diabetic vs non diabetic
people were estimated. Both logistic and gamma models
were adjusted for age and sex; educational level was not
included in the final model as its contribution was not
statistically significant. Estimated costs for diabetic and non
diabetic people were then calculated multiplying thebetic and non diabetic people: The population-based Turin study,
1016/j.numecd.2011.04.007
Table 1 Characteristics of diabetic and non diabetic people of the Turin Study.
Diabetic people Non diabetic people
N. People with zero cost N. People with zero cost
N. % N. %
All cohort 33,792 433 1.3 863,123 185,711 21.5
Sex
Men 17,152 253 1.5 411,967 111,495 27.1
Women 16,640 180 1.1 451,156 74,216 16.5
Age group (year)
<45 1671 43 2.6 449,958 131,520 29.2
45e54 3008 62 2.1 116,556 25,945 22.3
55e64 7725 90 1.2 115,747 16,592 14.3
65e74 11,508 98 0.9 101,366 7145 7.1
>74 9880 140 1.4 79,496 4509 5.7
Type of diabetes
Type 1 1703 21 1.2
Type 2 32,089 412 1.3
Treatment
Diet 7087 433 6.1
Oral drugs 17,828 0 0
Insulin 8877 0 0
Direct costs in diabetic people 3
+ MODELexpected probability of spending for health care by the
estimated costs for people using health care. Confidence
intervals (95% CI) for estimated costs were calculated by
a bootstrap process with 100 samples. Separate models were
performed by sex, age groups (<45, 45e54, 55e64,
65e74>74 years), type of diabetes and antidiabetic treat-
ment. Costs were estimated by health care services (hospi-
talization, emergency care, outpatient care, drugs,
consumable goods); we also analyzed hospitalization data by
main diagnosis and outpatient care data by clinical unit,
according to the same methodological approach. Statistical
analyses were conducted using SAS System, version 9.1.
Results
The study base included 33,792 diabetic and 863,123 non-
diabetic people living in the city of Turin on July 31, 2003.Table 2 Estimated direct costs of diabetic and non diabetic pe














a derived by two parts models, adjusted for age and sex.
b derived by bootstrapping method.
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Italy, Nutrition, Metabolism & Cardiovascular Diseases (2011), doi:10.1Mean age of diabetic and non-diabetic people was 67.7
years and 44.3 years, respectively. Of the diabetic cohort,
21.0% were treated with diet, 52.8% with oral drugs and
26.2% with insulin; 1703 people (0.05%) where considered
as type 1 diabetes, while 32,089 people (99.5%) as type 2
diabetes.
Costs data were typically skewed because a relatively
small proportion of people incurred extremely high costs,
whereas a subgroup (21.5% among non diabetic people and
1.3% among diabetic people) had zero costs (Table 1). As
shown in Table 2, estimated direct costs/year were V
3660.8 in diabetic people and V 895.6 in non-diabetic
people (cost ratio Z 4.1). The excess of direct cost in
diabetic than in non diabetic people was similar between
sexes, whereas it was strongly affected by age, being 7-fold
higher in people aged <45 years and 1.7-fold higher in
those aged >74 years.ople in the Turin Study.
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Table 3 Estimated costs of diabetic and non diabetic people in the Turin Study, by health care service.
Diabetic people (N Z 33,792) Non diabetic people (N Z 863,123) Cost ratio
People with
0 cost N (%)
Cost (V) per
person/yeara






Hospitalizations 24,482 (72.5) 2065.4 2051.1e2079.8 768,788 (89.1) 664.4 661.7e667.6 3.1
Emergency
care
24,886 (73.6) 31.5 31.4e31.7 680,740 (78.9) 16.55 16.54e16.56 1.9
Outpatient care 2466 (7.3) 427.7 426.9e428.7 356,363 (41.3) 151.4 151.2e151.6 1.8
Drugs 1233 (3.7) 923.6 920.9e926.5 327,915 (38.0) 222.9 222.6e223.4 2.8
Consumable
goods
17,071 (50.5) 154.5 154.0e154.9 861,062 (99.8) 0.628 0.622e0.633 246.0
a derived by two parts models, adjusted for age and sex.
b derived by bootstrapping method.
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+ MODELTable 3 shows estimated costs in diabetic and diabetic
people by health care services; apart from consumable
goods, the highest difference between diabetic and non
diabetic people was found for drug costs (costs ratio Z 2.8)
and the lowest for outpatient care (cost ratio Z 1.7). The
distribution of direct costs among health care services was
almost unaffected by the disease: in diabetic people, 57.2%
of direct costs were due to hospitalizations (vs 62.9% among
non diabetic people), 25.6% to drugs (vs. 21.1%), 11.9% to
outpatient care (vs. 14.3%), 0.9% to emergency care (vs.
1.6%) and 4.4% to consumable goods related to diabetes
care (nearly absent in non diabetic people).
As shown in Table 4, people with type 1 diabetes had the
highest overall estimated costs, mainly due to the highest
employment of consumable goods (5-fold higher in type 1
than type 2 diabetes). Diabetic people treated with diet
only had higher estimated costs for hospitalizations and
outpatient care than people treated with oral drugs,
whereas insulin-treated people had the highest estimated
costs in each expenditure category.
Table 5 shows costs for hospitalizations and outpatients
services in diabetic and non diabetic people; cardiovascular
and kidney diseases were themost common complications of
the disease requiring hospitalization and outpatient care.Discussion
This report provides a comprehensive picture of direct costs
for diabetes in a large city of Northern Italy, under the
coverage of the universalistic National Health System. In
2003e2004 the per capita direct costs for diabetes were V
3661/year (w4575 USD). Considering a prevalence of dia-
betes of 4.8% [3,19,20], we can estimate that in the whole
Piedmont Region (4,330,000 inhabitants in 2004; Turin the
main city) at least 208,000 persons had diabetes, accounting
forV 761millions of direct costs, that is 11.4% of total health
care expenditures [21]. The health care cost of a personwith
diabetes was 4 fold higher than a person without diabetes of
similar age and sex. The impact of the disease was highest in
insulin-treated people and in the youngest age group. The
distribution of costs among categories of health care services
was rather similar between diabetic and non-diabetic
people, the largest proportion of costs being due to inpatientPlease cite this article in press as: Bruno G, et al., Direct costs in dia
Italy, Nutrition, Metabolism & Cardiovascular Diseases (2011), doi:10.care. Apart from consumable goods, the largest differences
in direct costs between persons with and without diabetes
were due to hospitalizations (3.1 folds) and drugs (2.8 folds).
These findings have implications for health care planners. As
increasing prevalence of the disease in developed countries
is mainly due to the increasing ageing of the general pop-
ulation and the improved survival of diabetic people [22],
diabetes-related health care costs are likely to increase
progressively in next years, having a profound impact on
National Health System expenditure. This expected trend
needs to be recognized by health care planners in order to
adequately allocate resources to manage the burden of the
disease.
Few studies have provided detailed data on direct costs of
diabetic and non-diabetic persons. Main limitations of
studies conducted in the United Stated [7e9], Canada [10],
Australia [11], Sweden [13], Spain [14], Germany [15] are: 1)
the recruitment of either clinic-based or health-insured
cohorts, thus limiting the generalizability of results; 2) the
limited number of recruited people, thus lowering the power
of estimates; 3) the absence of comparative data of non
diabetic people living in the same area, thus not allowing to
control estimates of costs for strong confounding factors,
such as age and sex. With regard to Italy, the ARNO study
provided similar results on direct costs; data in diabetic
people, however, were compared to pharmacologically-
treated non-diabetic people, thus providing biased down-
ward estimates of excess of costs in diabetic people [23]. Our
study, based on a large population-based cohort of both
diabetic and non-diabetic people, provides actual rather
than estimated data, and strong evidence of heterogeneities
in health care costs depending on age, type of diabetes and
treatment. Although the highest costs were due to care of
the elderlywith diabetes, the same increasing trend by age is
evident also in non-diabetic people. The final result is that
the highest costs ratio is that of the youngest people (7-fold
excess) whereas in the elderly this excess was 70% only. In
absolute terms, however, the elderly were responsible for
the highest proportion of consumption of health care
resources. In the last decade, prevalence of diabetes has
more than doubled in people aged 75 years and over [3], thus
the impact of the disease on National Health System will
probably be much stronger in next years [22,24]. In Europe,
Italy is the third country for expected years of life in peoplebetic and non diabetic people: The population-based Turin study,
1016/j.numecd.2011.04.007
Table 4 Estimated direct costs of diabetic people in the Turin Study, Italy, by type of diabetes and treatment.
Cost (V) per
person/yeara
CI 95%b Diabetic/non diabetic
cost ratio
All services
Type 1 diabetes 4406.8 4304.1e4521.9 4.9
Type 2 diabetes 3532.8 3522.7e3544.9 3.9
Treatment
Diet 3389.2 3354.1e3415.7 3.8
Oral drugs 2511.1 2502.2e2522.3 2.8
Insulin 6038.8 5988.2e6082.7 6.7
Hospitalizations
Type 1 diabetes 1703.3 1602.7e1811.7 2.6
Type 2 diabetes 2071.0 2058.4e2086.0 3.1
Treatment
Diet 2231.9 2200.9e2263.3 3.4
Oral drugs 1449.3 1435.8e1461.4 2.2
Insulin 3130.6 3091.2e3164.9 4.7
Emergency care
Type 1 diabetes 31.8 31.2e32.3 1.9
Type 2 diabetes 31.5 31.3e31.6 1.9
Treatment
Diet 29.5 29.1e29.8 1.8
Oral drugs 27.5 27.3e27.7 1.7
Insulin 41.1 40.7e41.4 2.5
Outpatient care
Type 1 diabetes 418.5 410.4e425.2 2.8
Type 2 diabetes 422.9 422.0e423.9 2.8
Treatment
Diet 451.0 448.0e454.3 3.0
Oral drugs 312.0 310.8e312.8 2.1
Insulin 618.3 614.9e621.2 4.1
Drugs
Type 1 diabetes 1165.3 1133.2e1207.0 5.2
Type 2 diabetes 884.7 882.3e887.2 4.0
Treatment
Diet 678.7 673.4e684.9 3.0
Oral drugs 772.6 770.4e775.6 3.5
Insulin 1376.9 1367.6e1387.1 6.2
Consumable goods
Type 1 diabetes 596.6 589.3e602.3 950.0
Type 2 diabetes 135.3 135.0e136.6 215.4
Treatment
Diet 11.7 11.5e11.9 18.6
Drugs 36.5 36.4e36.6 58.1
Insulin 515.9 514.0e518.0 821.5
a derived by two parts models, adjusted for age and sex.
b derived by bootstrapping method.
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+ MODELaged 50 years, after Denmark and Malta [25]. On the other
hand, involving mainly retired people, direct costs of dia-
betes should increase more than indirect costs, that is
productivity losses associated with the illness. Data on
indirect costs of diabetic people living in European coun-
tries, however, are very limited [14].
The highest direct costs of diabetic people were due to
inpatient care. Large regional variations in hospitalization
rates have been found within Italy; as the availability of
outpatients services are inversely related to hospitaliza-
tions [26], diabetologists, general practitioners and healthPlease cite this article in press as: Bruno G, et al., Direct costs in dia
Italy, Nutrition, Metabolism & Cardiovascular Diseases (2011), doi:10.1care planners should take into proper consideration these
data to reduce health care costs. Moreover, our data shows
that people treated with diet only had higher costs for
hospitalizations and outpatient care that people treated
with oral drugs, suggesting the hypothesis that in this
subgroup of diabetic people the quality of control of the
disease might be inadequate due to therapeutic inertia.
Unfortunately, no clinical data are available at present to
test this hypothesis. In this cohort, one third of costs for
hospitalizations was due to cardiovascular diseases; as
diabetes has generally an extended asymptomatic period,betic and non diabetic people: The population-based Turin study,
016/j.numecd.2011.04.007
Table 5 Estimated costs for inpatient and outpatient care of diabetic and non diabetic people in the Turin Study.
Diabetic people Non diabetic people Cost ratio
Cost (V) per
person/yeara




Cardiovascular diseases 795.6 782.2e808.5 245.5 242.6e247.9 3.2
Neoplastic diseases 223.2 220.0e227.0 119.0 117.8e120.1 1.9
Respiratory diseases 196.2 187.2e204.5 55.8 54.7e57.2 3.5
Kidney diseases 68.2 67.1e69.2 29.0 28.8e29.3 2.3
Diabetes 90.8 86.2e94.6 0.2 0.14e0.19 e
Day hospital 276.2 273.8e279.1 138.2 137.5e138.7 2.0
Outpatient care
Cardiology 22.1 22.0e22.2 10.2 10.16e10.24 2.2
Vascular surgery 1.6 1.54e1.63 0.5 0.53e0.55 3.2
Diabetology/endocrinology 33.6 33.5e33.7 1.8 1.77e1.79 18.7
Internal medicine 8.8 8.7e8.9 2.3 2.26e2.29 3.8
Nephrology 113.7 112.0e115.8 26.8 26.4e27.3 4.2
Oculist 15.3 15.2e15.4 4.1 4.12e4.15 3.7
Radiology 63.3 63.1e53.5 39.9 39.77e39.94 1.6
Laboratory 82.1 81.9e82.2 33.1 33.0e33.1 2.5
a derived by two parts models, adjusted for age and sex.
b derived by bootstrapping method.
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+ MODELearly diagnosis should be implemented, particularly in
middle-aged people, to reduce cardiovascular complica-
tions and related costs.
Main strengths of our study are:1) the recruitment of
a population-based (i.e. unselected) cohort of diabetic and
non diabetic people covered by the National Health System;
2) the inclusion of all available data of the National Health
System, thus allowing to provide actual direct costs sus-
tained for diabetes care rather than their estimates; 3) the
availability of comparative data of non diabetic people
living in the same area, thus allowing to control estimates
for strong confounding factors, such as age and sex. Several
limitations must be recognized. At first, the absence of
individual data on diabetes duration, severity of the disease
and indicators of diabetes control, such as HbA1c, blood
pressure and lipids did not allow to explore the relationship
between costs sustained by the National Health System and
the quality of care provided to diabetic people. Second, it
has been shown that the real cost for hospitalization for
each DRG, which is an average cost, is higher for diabetic
than for non-diabetic people [15], therefore our data may
be underestimated. Finally, we did not consider indirect
costs or informal care costs.
In conclusion, the population-based Turin study shows
that direct costs of diabetic people are 4-fold higher than
non-diabetic people, independently of age and sex. The
large amount of direct costs is due to the care of the elderly
diabetic people and inpatient care. From a public health
perspective there is the need to recognize that in developed
countries demographic changes will necessarily have
a profound impact on direct costs for diabetes in next years.Funding
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